AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

AbCellera (Nasdaq: ABCL) today announced that the Company will participate in the following investor conferences:

  • Truist Securities BioPharma Symposium, November 6, 2025
  • Stifel Healthcare Conference, November 11-13, 2025
  • Jefferies Global Healthcare Conference, November 18-20, 2025
  • Piper Sandler 37th Annual Healthcare Conference, December 2-4, 2025

Visit AbCellera's Investor Relations website for additional information.

About AbCellera Biologics Inc .

AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women's health, immunology, and oncology. For more information, please visit www.abcellera.com .

Inquiries
Media: Tiffany Chiu; media@abcellera.com , +1(236)521-6774
Partnering: Murray McCutcheon, Ph.D.; partnering@abcellera.com , +1(604)559-9005
Investor Relations: Peter Ahn; ir@abcellera.com , +1(778)729-9116

News Provided by Business Wire via QuoteMedia

AbCellera Biologics Inc.ABCLNASDAQ:ABCLLife Science Investing
ABCL
The Conversation (0)
AbCellera Biologics Inc.

AbCellera Biologics Inc.

Quantum Biopharma

Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock

Reward to be Paid if Information Contributes Significant Evidence Leading to a Trial Victory or Settlement in Landmark USD $700 Million+ Lawsuit

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol... Keep Reading...
Imagion Biosystems

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, is pleased to provide shareholders with a progress update regarding the Company’s business and... Keep Reading...
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare. But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no... Keep Reading...
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This... Keep Reading...
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access... Keep Reading...
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will... Keep Reading...

Latest News

More News

Latest Press Releases

Western Uranium & Vanadium Announces Brokered LIFE Financing of $5 Million

InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors

CHARBONE Hydrogen Successfully Completes the Dismantling of Hydrogen Equipment in Quebec and Announces the Arrival of the Main Components in Sorel-Tracy

CHARBONE Hydrogene complete avec succes le demantelement des equipements d'hydrogene a Quebec et annonce l'arrivee des principales composantes a Sorel-Tracy

Related News

Uranium Investing

Western Uranium & Vanadium Announces Brokered LIFE Financing of $5 Million

Gold Investing

Predictive Discovery and Robex Merge, Combining West African Gold Projects

Tech Investing

CHARBONE Hydrogen Successfully Completes the Dismantling of Hydrogen Equipment in Quebec and Announces the Arrival of the Main Components in Sorel-Tracy

Tech Investing

CHARBONE Hydrogene complete avec succes le demantelement des equipements d'hydrogene a Quebec et annonce l'arrivee des principales composantes a Sorel-Tracy

Battery Metals Investing

Trading Halt

Battery Metals Investing

Western Uranium & Vanadium Announces Brokered LIFE Financing of $5 Million

resource investing

Nine Mile Metals Closes Oversubscribed Non Flow Through Private Placement